{"id":692772,"date":"2022-10-06T07:23:08","date_gmt":"2022-10-06T11:23:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/"},"modified":"2022-10-06T07:23:08","modified_gmt":"2022-10-06T11:23:08","slug":"provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/","title":{"rendered":"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <i>Provention receives <span class=\"xn-money\">$20 million<\/span> nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D <\/i>\n        <\/li>\n<li>\n          <i>U.S. copromotion agreement leverages Sanofi&#8217;s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening<\/i>\n        <\/li>\n<li>\n          <i>Sanofi to invest <span class=\"xn-money\">$35 million<\/span> at a premium after a potential teplizumab FDA approval <\/i>\n        <\/li>\n<li>\n          <i>Investor Conference call at <span class=\"xn-chron\">8:30am ET<\/span> Today<\/i>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-person\">RED BANK<\/span>, N.J.\u00a0<\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 6, 2022<\/span><\/span> \/PRNewswire\/ &#8212; Provention Bio, Inc. (Nasdaq: PRVB) (the &#8220;Company&#8221;), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention&#8217;s lead investigational drug candidate teplizumab. The agreement enables Provention Bio to leverage Sanofi&#8217;s expertise, capabilities and commercial resources to support the potential launch of teplizumab currently under review by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), for the delay of clinical type 1 diabetes in at-risk individuals, with a user fee goal date of <span class=\"xn-chron\">November 17, 2022<\/span> for the Biologics License Application.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg\" title=\"(PRNewsfoto\/Provention Bio, Inc.)\" alt=\"(PRNewsfoto\/Provention Bio, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>&#8220;This collaboration with Sanofi U.S. allows us to significantly expand our planned commercial footprint during launch to support increased screening and product awareness as we work to launch a new therapy that, if approved, will dramatically impact the lives of the patients and families we serve,&#8221; said <span class=\"xn-person\">Jason Hoitt<\/span>, Chief Commercial Officer, Provention Bio. &#8220;In particular, Sanofi&#8217;s long-standing relationships with key U.S. healthcare professionals will complement our focus on pediatric endocrinologists and help us address a larger patient population with greater efficiency.&#8221;<\/p>\n<p>Olivier Bogillot, Head of U.S. General Medicines, Sanofi, stated, &#8220;We are delighted by the prospect of supporting Provention Bio in bringing to the U.S. what could become the first-in-class therapy to change the course of type 1 diabetes. If approved, Sanofi U.S. will leverage its existing world-class capabilities in diabetes care to enhance efforts in both patient and healthcare provider access. We are prepared to tap into all of our internal expertise to support the successful launch of this innovative therapy.&#8221;<\/p>\n<p>&#8220;The agreement brings significant resources to Provention and allows us to advance our mission of delivering therapies which intercept or delay debilitating and life-threatening autoimmune diseases,&#8221; said <span class=\"xn-person\">Ashleigh Palmer<\/span>, Co-Founder and Chief Executive Officer, Provention Bio. &#8220;We look forward to working with our colleagues at Sanofi as we prepare to deliver, if approved, the first-ever disease-modifying therapy for T1D.&#8221;<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>Co-Promotion Agreement\u00a0<\/b>\n      <\/div>\n<p>Under the terms of the agreement, Sanofi will commit commercial resources\u00a0in <span class=\"xn-location\">the United States<\/span>, including diabetes field specialists, account directors, field-based reimbursement and medical science liaisons to expand the number of key healthcare professionals reached in <span class=\"xn-location\">the United States<\/span>. In exchange, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement.\u00a0<\/p>\n<p>Provention retains all rights to teplizumab and maintains responsibility for the commercialization strategy.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>Right of First Negotiation to Global Commercial Rights<\/b>\n      <\/div>\n<p>The Company also granted Sanofi, in consideration of a one-time payment of <span class=\"xn-money\">$20 million<\/span>, an exclusive, one-time right of first negotiation (ROFN) to obtain exclusive global rights to commercialize teplizumab for Type 1 diabetes indications in humans, subject to certain retained rights of the Company to engage in discussions with third parties with respect to certain transactions. Sanofi may exercise the ROFN, until <span class=\"xn-chron\">June 30, 2023<\/span>, with an option to extend within 2023 under certain conditions.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>Equity Investment<\/b>\n      <\/div>\n<p>Simultaneous with their entry into the co-promotion agreement, the Company and Sanofi entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;). Pursuant to the Purchase Agreement, if teplizumab is approved by the FDA, Sanofi has agreed to purchase <span class=\"xn-money\">$35 million<\/span> of the Company&#8217;s common stock at a premium over the daily volume-weighted average per share price for the five consecutive trading days prior to the closing date. The closing date will be at Provention&#8217;s discretion and would occur no later than <span class=\"xn-chron\">February 16, 2023<\/span>.<\/p>\n<p>BofA Securities acted as financial advisor to the Company on this transaction.<\/p>\n<p>For important information related to the terms of the Co-Promotion Agreement and Securities Purchase Agreement, see Provention Bio&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on <span class=\"xn-chron\">October 6, 2022<\/span>.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>Conference Call and Webcast Information<\/b>\n      <\/div>\n<p>Provention Bio will discuss this business update via conference call today at\u00a08:30 am\u00a0ET. To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the &#8220;Provention Bio Call.&#8221; An audio webcast will also be available on the &#8220;Events and Webcasts&#8221; page of the Investors section of the Company&#8217;s website,\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3668595-1&amp;h=2191855475&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3612285-1%26h%3D240049532%26u%3Dhttp%253A%252F%252Fwww.proventionbio.com%252F%26a%3Dwww.proventionbio.com&amp;a=www.proventionbio.com\" target=\"_blank\" rel=\"nofollow noopener\">www.proventionbio.com<\/a>. An archived webcast will be available on the Company&#8217;s website approximately two hours after the conference call.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>About Teplizumab<\/b>\n      <\/div>\n<p>Teplizumab is an anti-CD3 monoclonal antibody that is being developed for the delay of clinical T1D in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies. There has been no disease-modifying innovation for this life-impacting and life-threatening autoimmune disease since the development of insulin a century ago. More than 800 patients have received teplizumab in multiple clinical studies involving more than 1,000 subjects. Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D (the Phase 3 PROTECT study).<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>About Provention Bio, Inc.<\/b>\n      <\/div>\n<p>Provention Bio, Inc. (Nasdaq:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3668595-1&amp;h=4164631798&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fprovention-bio-announces-senior-leadership-addition-301626595.html%23financial-modal&amp;a=PRVB\" target=\"_blank\" rel=\"nofollow noopener\">PRVB<\/a>) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to Stage 3 clinical type 1 diabetes in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The Company&#8217;s pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and\/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3668595-1&amp;h=490396662&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3651156-1%26h%3D1216048222%26u%3Dhttps%253A%252F%252Fproventionbio.com%252F%26a%3Dwww.ProventionBio.com&amp;a=www.ProventionBio.com\" target=\"_blank\" rel=\"nofollow noopener\">www.ProventionBio.com<\/a>\u00a0for more information and follow us on Twitter: @ProventionBio.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>Internet Posting of Information<\/b>\n      <\/div>\n<p>Provention Bio, Inc. uses its website,\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3668595-1&amp;h=3359756044&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3651156-1%26h%3D4257325410%26u%3Dhttps%253A%252F%252Fproventionbio.com%252F%26a%3Dwww.proventionbio.com&amp;a=www.proventionbio.com\" target=\"_blank\" rel=\"nofollow noopener\">www.proventionbio.com<\/a>, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company&#8217;s website in the &#8220;News&#8221; section. Accordingly, investors should monitor this portion of the Company&#8217;s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold;text-align: left\" role=\"heading\">\n        <b>Forward-Looking Statements<\/b>\n      <\/div>\n<p>Certain statements in this press release are forward-looking, including but not limited to, statements relating to the Company&#8217;s ability to leverage Sanofi&#8217;s expertise, capabilities and commercial resources to support the potential launch of teplizumab, the potential that the collaboration with Sanofi to significantly expand the Company&#8217;s planned commercial footprint during launch, the potential exercise of the ROFN by Sanofi, the potential approval and commercialization of teplizumab and the potential closing of the common stock offering to Sanofi. These statements may be identified by the use of forward-looking words such as &#8220;may&#8221; and &#8220;potential,&#8221; among others. These forward-looking statements are based on the Company&#8217;s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to FDA disagreeing with the Company&#8217;s interpretation of data and analysis and information in the BLA resubmission; delays in or failure to obtain FDA approvals for teplizumab or other Company product candidates and the potential for noncompliance with FDA regulations; any inability to successfully work with FDA to address its concerns and requests in a timely manner or at all during the review process for teplizumab, including any inability to provide the FDA with data, analysis or other information sufficient to support an approval of the BLA for teplizumab; any inability to satisfactorily address matters related to PK comparability, product quality, safety or any other FDA requirements during the BLA review process to obtain an approval of teplizumab; the potential impacts of COVID-19 on our business and financial results; changes in law, regulations, or interpretations and enforcement of regulatory guidance; uncertainties of patent protection and litigation; the Company&#8217;s dependence upon third parties; substantial competition; the Company&#8217;s need for additional financing and the risks listed under &#8220;Risk Factors&#8221; in the Company&#8217;s quarterly report on Form 10-Q for the quarter ended <span class=\"xn-chron\">June 30, 2022<\/span> and any subsequent filings with the Securities and Exchange Commission. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Provention does not undertake an obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. The information set forth herein speaks only as of the date hereof.<\/p>\n<p>\n        <b>Investor Contacts:<br \/><\/b>Thierry Chauche, Chief Financial Officer<br \/><a href=\"mailto:tchauche@proventionbio.com\" target=\"_blank\" rel=\"nofollow noopener\">tchauche@proventionbio.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Brendan Strong<\/span><br \/>\n        <br \/>Argot Partners<br \/><a href=\"mailto:Proventionbio@argotpartners.com\" target=\"_blank\" rel=\"nofollow noopener\">Proventionbio@argotpartners.com<\/a><br \/>212-600-1902<\/p>\n<p>\n        <b>Media Contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Kaelan Hollon<\/span>, VP of Communications<br \/><a href=\"mailto:khollon@proventionbio.com\" target=\"_blank\" rel=\"nofollow noopener\">khollon@proventionbio.com<\/a>\u00a0<br \/>202-421-4921<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY93918&amp;sd=2022-10-06\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-us-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals-301642021.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-us-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals-301642021.html<\/a><\/p>\n<p>SOURCE  Provention Bio, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY93918&amp;Transmission_Id=202210060700PR_NEWS_USPR_____NY93918&amp;DateId=20221006\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D U.S. copromotion agreement leverages Sanofi&#8217;s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening Sanofi to invest $35 million at a premium after a potential teplizumab FDA approval Investor Conference call at 8:30am ET Today RED BANK, N.J.\u00a0, Oct. 6, 2022 \/PRNewswire\/ &#8212; Provention Bio, Inc. (Nasdaq: PRVB) (the &#8220;Company&#8221;), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention&#8217;s lead investigational drug candidate teplizumab. The agreement enables Provention Bio to leverage Sanofi&#8217;s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692772","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D U.S. copromotion agreement leverages Sanofi&#8217;s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening Sanofi to invest $35 million at a premium after a potential teplizumab FDA approval Investor Conference call at 8:30am ET Today RED BANK, N.J.\u00a0, Oct. 6, 2022 \/PRNewswire\/ &#8212; Provention Bio, Inc. (Nasdaq: PRVB) (the &#8220;Company&#8221;), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention&#8217;s lead investigational drug candidate teplizumab. The agreement enables Provention Bio to leverage Sanofi&#8217;s &hellip; Continue reading &quot;Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T11:23:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals\",\"datePublished\":\"2022-10-06T11:23:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/\"},\"wordCount\":1511,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/\",\"name\":\"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\",\"datePublished\":\"2022-10-06T11:23:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/720849\\\/Provention_Bio_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/","og_locale":"en_US","og_type":"article","og_title":"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals - Market Newsdesk","og_description":"PR Newswire Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D U.S. copromotion agreement leverages Sanofi&#8217;s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening Sanofi to invest $35 million at a premium after a potential teplizumab FDA approval Investor Conference call at 8:30am ET Today RED BANK, N.J.\u00a0, Oct. 6, 2022 \/PRNewswire\/ &#8212; Provention Bio, Inc. (Nasdaq: PRVB) (the &#8220;Company&#8221;), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention&#8217;s lead investigational drug candidate teplizumab. The agreement enables Provention Bio to leverage Sanofi&#8217;s &hellip; Continue reading \"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T11:23:08+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals","datePublished":"2022-10-06T11:23:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/"},"wordCount":1511,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/","name":"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","datePublished":"2022-10-06T11:23:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/720849\/Provention_Bio_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provention-bio-to-combine-forces-with-sanofi-to-support-potential-u-s-launch-of-teplizumab-for-delay-in-onset-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692772"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692772\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}